We are live on ! Find out more
QUSVM

Qiming U.S. Ventures Management Portfolio holdings

AUM $55.6M
1-Year Est. Return 98.09%
This Fund
S&P 500
This Quarter Est. Return
+77.56%
1 Year Est. Return
+98.09%
3 Year Est. Return
+1,484.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$109M
AUM Growth
+$33.9M
Cap. Flow
+$19.1M
Cap. Flow %
17.49%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
KRRO icon
Korro Bio
KRRO
+$12.1M
2
TRML
Tourmaline Bio
TRML
+$6.97M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICVX
1
DELISTED
Icosavax, Inc. Common Stock
ICVX
$55.3M 50.66%
3,510,228
– –
KRRO icon
2
Korro Bio
KRRO
$153M
$17.6M 16.15%
+368,085
New +$12.1M
TRML
3
DELISTED
Tourmaline Bio
TRML
$16.8M 15.38%
641,691
+348,430
+119% +$6.97M
HLVX
4
DELISTED
HilleVax
HLVX
$8.97M 8.21%
558,923
– –
JSPR icon
5
Jasper Therapeutics
JSPR
$22.4M
$6.72M 6.16%
851,965
– –
VTYX
6
DELISTED
Ventyx Biosciences
VTYX
$1.7M 1.55%
686,370
– –
ELEV
7
DELISTED
Elevation Oncology
ELEV
$1.27M 1.17%
2,370,142
– –
KZR
8
DELISTED
Kezar Life Sciences
KZR
$785K 0.72%
82,871
– –

Similar funds

CCCPV
Castle Creek Capital Partners VI San Diego, California $55.9M AUM 7.91% 1-Year Est. Return
ACM
Aurelius Capital Management New York $55.2M AUM 124.79% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
NCFG
New Century Financial Group Princeton, New Jersey $56.3M AUM 16.99% 1-Year Est. Return
LAM
Lingohr Asset Management Duesseldorf, Germany $57.3M AUM 35.27% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
ITVII
IDG Technology Venture Investment IV Hong Kong $58.3M AUM 89.42% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Qiming U.S. Ventures Management's Q4 2023 Portfolio in Review

As of Q4 2023, Qiming U.S. Ventures Management held 8 positions worth $109M, up 45% from $75.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Qiming U.S. Ventures Management deployed $19.1M of net new capital in Q4 2023, opening 1 new position and adding to 1 existing holding. Its largest new stake was Korro Bio: 368,085 shares worth $17.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Qiming U.S. Ventures Management's largest Q4 2023 buy was Korro Bio: 368,085 shares worth $17.6M.
  • Qiming U.S. Ventures Management added most to Tourmaline Bio in Q4 2023, an estimated $6.97M increase.
  • Qiming U.S. Ventures Management's ten largest holdings make up 100% of its $109M portfolio in Q4 2023.
  • Qiming U.S. Ventures Management opened 1 new position and closed 0 in Q4 2023.
  • Qiming U.S. Ventures Management's portfolio value rose 45% quarter-over-quarter to $109M.

Based on Qiming U.S. Ventures Management's 13F filing for Q4 2023, filed 14 Feb 2024.